Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Emtricitabine/tenofovir disoproxil fumarate - Gilead Sciences

Next Previous
Drug Profile

Emtricitabine/tenofovir disoproxil fumarate - Gilead Sciences

Alternative Names: Emtricitabine/tenofovir-disoproxil; Emtriva®/Viread®; FTC/TDF; TDF/FTC; Tenofovir disoproxil fumarate/emtricitabine; Truvada; TVD; Viread®/Emtriva®

Latest Information Update: 03 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences
  • Developer Gador; Gilead Sciences; Japan Tobacco; National Institute of Allergy and Infectious Diseases; Stendhal Mexico; University of Alberta; University of Washington
  • Class Antiretrovirals; Deoxyribonucleosides; Nucleotides; Phosphonic acids; Purines; Pyrimidine nucleosides
  • Mechanism of Action Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV infections
  • Phase III Hepatitis B
  • Phase II Primary biliary cirrhosis

Most Recent Events

  • 03 Mar 2024 Pharmacodynamics data from a preclinical trial in HIV infections presented 31st Conference on Retroviruses and Opportunistic Infections 2024 (CROI-2024) .
  • 01 Jan 2024 University of Alberta in collaboration with Merck Sharp & Dohme completes a phase II trial in Primary biliary cirrhosis (Combination therapy) in Canada (PO) (NCT03954327)
  • 26 Oct 2023 Gilead Sciences plans a phase II PURPOSE-4 trial for HIV Infection (Prevention, Combination therapy) in December 2023 (NCT06101342)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top